{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:39:10Z","timestamp":1770781150119,"version":"3.50.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36899-z","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T03:35:42Z","timestamp":1768793742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and survival outcomes of adult inflammatory myofibroblastic tumor: a retrospective single-center study"],"prefix":"10.1038","volume":"16","author":[{"given":"Ay\u015feg\u00fcl","family":"Dumluda\u011f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gizem","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Topal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esmanur Kaplan","family":"T\u00fcz\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berkan","family":"Karadurmu\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130smail","family":"Ert\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuri","family":"Karadurmu\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"4","key":"36899_CR1","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/01.pas.0000213393.57322.c7","volume":"31","author":"CM Coffin","year":"2007","unstructured":"Coffin, C. M., Hornick, J. L. & Fletcher, C. D. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am. J. Surg. Pathol. 31 (4), 509\u2013520 (2007).","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"36899_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jcp.2007.049387","volume":"61","author":"BC Gleason","year":"2008","unstructured":"Gleason, B. C. & Hornick, J. L. Inflammatory myofibroblastic tumours: where are we now? J. Clin. Pathol. 61 (4), 428\u2013437 (2008).","journal-title":"J. Clin. Pathol."},{"key":"36899_CR3","unstructured":"WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours 5th edn (IARC, 2020)."},{"key":"36899_CR4","doi-asserted-by":"crossref","unstructured":"Butrynski, J. E. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N. Engl. J. Med. 363 (18), 1727\u20131733. (2010).","DOI":"10.1056\/NEJMoa1007056"},{"issue":"2","key":"36899_CR5","first-page":"397","volume":"13","author":"CM Lovly","year":"2014","unstructured":"Lovly, C. M. et al. Molecular profiling of inflammatory myofibroblastic tumors: implications for diagnosis and therapy. Mol. Cancer Ther. 13 (2), 397\u2013403 (2014).","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"36899_CR6","first-page":"223","volume":"12","author":"DC McMillan","year":"2009","unstructured":"McMillan, D. C. Systemic inflammation, nutritional status and survival in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care. 12 (3), 223\u2013226 (2009).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"issue":"6","key":"36899_CR7","first-page":"2961","volume":"36","author":"Y Shibayama","year":"2016","unstructured":"Shibayama, Y. et al. Prognostic impact of serum albumin in patients with soft tissue sarcoma. Anticancer Res. 36 (6), 2961\u20132966 (2016).","journal-title":"Anticancer Res."},{"issue":"9","key":"36899_CR8","first-page":"4713","volume":"7","author":"T Nakamura","year":"2018","unstructured":"Nakamura, T. et al. Elevated C-reactive protein represents a potential biomarker in patients with soft tissue sarcoma. Cancer Med. 7 (9), 4713\u20134720 (2018).","journal-title":"Cancer Med."},{"issue":"11","key":"36899_CR9","first-page":"2985","volume":"21","author":"BJ Laird","year":"2013","unstructured":"Laird, B. J. et al. The systemic inflammatory response and survival in patients with advanced cancer. Support Care Cancer. 21 (11), 2985\u20132991 (2013).","journal-title":"Support Care Cancer"},{"key":"36899_CR10","unstructured":"Moss\u00e9, Y. P. et al. Targeting ALK gene variants in neuroblastoma with Crizotinib. N. Engl. J. Med. 368 (25), 2350\u20132356. (2013)."},{"issue":"4","key":"36899_CR11","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","volume":"7","author":"Demetri","year":"2017","unstructured":"DemetriGD et al. Efficacy and safety of Crizotinib in patients with advanced ALK-positive tumors other than NSCLC. Cancer Discov. 7 (4), 400\u2013409 (2017).","journal-title":"Cancer Discov"},{"key":"36899_CR12","unstructured":"Kurihara, H. et al. Crizotinib in anaplastic lymphoma kinase-positive IMT: long-term response. Cancer 121 (20), 3692\u20133699. (2015)."},{"issue":"3","key":"36899_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/annonc\/mdx774","volume":"29","author":"P Sch\u00f6ffski","year":"2018","unstructured":"Sch\u00f6ffski, P. et al. Activity of Crizotinib in advanced, ALK-positive IMT: EORTC CREATE trial. Ann. Oncol. 29 (3), 758\u2013765 (2018).","journal-title":"Ann. Oncol."},{"issue":"8","key":"36899_CR14","first-page":"757","volume":"48","author":"R Umezawa","year":"2018","unstructured":"Umezawa, R. et al. A case of metastatic inflammatory myofibroblastic tumor successfully treated with ALK inhibitor. Jpn J. Clin. Oncol. 48 (8), 757\u2013761 (2018).","journal-title":"Jpn J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36899-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36899-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36899-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T23:03:20Z","timestamp":1770764600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36899-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36899"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36899-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of the Health Sciences University G\u00fclhane Training and Research Hospital (Approval No: 2023\/223, Date: 11.10.2023). The requirement for informed consent was waived by the committee due to the retrospective nature of the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"5733"}}